In 2026, the spotlight will be on a handful of therapeutic strategies that could change cancer care for patients by offering ...

DS-9606 was supposed to be the first antibody-drug conjugate in Daiichi Sankyo’s line of anti-cancer assets to use a modified ...

Shares of Prelude Therapeutics rose after the company said it has received Food and Drug Administration approval to proceed with a Phase 1 study for blood-cancer treatment. Shares were up 9.4% at ...

Many breast cancer drugs block estrogen receptors inside cancer cells. Blocking the receptors early in disease progression staves off metastasis. But most patients with advanced disease eventually ...

Researchers found an antibody that seems to play a role in people with better lung cancer prognoses, but turning it into a ...

Lantern showcases two commercially ready, machine learning platforms that have the potential to accelerate drug discovery from months to days and dramatically reduce costs. predictBBB.ai and LBx-AI, ...

An international research consortium, led by scientists at VIB and UGent, has developed a new platform that could change how ...

BOSTON, MA, UNITED STATES, January 15, 2026 /EINPresswire.com/ -- Oncoheroes Biosciences, a biotech company exclusively ...

Lupin has launched generic cancer drug Dasatinib Tablets, in multiple strengths, in the U.S. The product, bioequivalent to Bristol-Myers Squibb Company’s Sprycel Tablets, was developed by Lupin in ...

ImmunityBio Chairman Patrick Soon-Shiong mischaracterized talks with the FDA over the company's cancer drug, sources say.

Advances in cancer research have led to an increasing number and variety of cancer therapies in the development pipeline, but there are concerns that traditional processes for drug development, ...

CAMBRIDGE, England--(BUSINESS WIRE)--Crescendo Biologics Ltd (Crescendo), the developer of novel, targeted, T cell enhancing therapeutics, and Cancer Research UK, the world’s largest independent ...